PTC Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
PTC Therapeutics, Inc. (PTCT) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$1.93 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-02-19
- PTC Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- PTC Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-09-30 was $0.00.
- PTC Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-06-30 was -$2.10M.
- PTC Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-03-31 was $166.00K, a 181.36% increase year-over-year.
- PTC Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was -$1.93M.
- PTC Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was -$2.68M.
- PTC Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was -$5.74M.
- PTC Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2021 was -$8.28M, a 143.01% decline from fiscal 2020.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | -$2.10M derived: sum of 3 quarters · filed 2026-02-19 | -$1.93M 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$2.10M derived: sum of 2 quarters · filed 2025-11-04 | -$1.93M 10-Q · filed 2025-11-04 | -$15.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.93M 10-Q · filed 2025-08-07 | -$15.00K derived: sum of 3 quarters · filed 2026-02-19 | -$3.07M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $166.00K 10-Q · filed 2025-05-06 | $2.08M derived: sum of 2 quarters · filed 2026-02-19 | -$973.00K derived: sum of 3 quarters · filed 2026-02-19 | -$2.57M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$1.14M derived: sum of 2 quarters · filed 2026-02-19 | -$2.74M derived: sum of 3 quarters · filed 2026-02-19 | -$2.68M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$3.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$4.65M derived: sum of 2 quarters · filed 2024-11-07 | -$4.59M 10-Q · filed 2024-11-07 | -$7.94M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.54M 10-Q · filed 2024-08-08 | -$4.89M derived: sum of 3 quarters · filed 2025-02-27 | -$9.27M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $59.00K 10-Q · filed 2024-04-25 | -$3.29M derived: sum of 2 quarters · filed 2025-02-27 | -$7.68M derived: sum of 3 quarters · filed 2025-02-27 | -$4.14M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$7.74M derived: sum of 2 quarters · filed 2025-02-27 | -$4.20M derived: sum of 3 quarters · filed 2025-02-27 | -$5.74M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$4.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | -$850.00K derived: sum of 2 quarters · filed 2023-10-26 | -$2.39M 10-Q · filed 2023-10-26 | -$12.73M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $3.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.00M 10-Q · filed 2023-08-03 | -$8.34M derived: sum of 3 quarters · filed 2024-02-29 | -$10.61M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$1.54M 10-Q · filed 2023-04-27 | -$11.88M derived: sum of 2 quarters · filed 2024-02-29 | -$14.15M derived: sum of 3 quarters · filed 2024-02-29 | -$17.68M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$10.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$12.61M derived: sum of 2 quarters · filed 2024-02-29 | -$16.14M derived: sum of 3 quarters · filed 2024-02-29 | -$8.28M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$2.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | -$5.80M derived: sum of 2 quarters · filed 2022-10-27 | $2.05M 10-Q · filed 2022-10-27 | $20.67M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | -$3.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $4.33M 10-Q · filed 2022-08-04 | $22.95M derived: sum of 3 quarters · filed 2023-02-21 | $24.33M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $7.86M 10-Q · filed 2022-05-03 | $26.48M derived: sum of 2 quarters · filed 2023-02-21 | $27.86M derived: sum of 3 quarters · filed 2023-02-21 | $29.91M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $18.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $20.00M derived: sum of 2 quarters · filed 2023-02-21 | $22.05M derived: sum of 3 quarters · filed 2023-02-21 | $19.25M 10-K · filed 2023-02-21 |
| 2020-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $3.43M derived: sum of 2 quarters · filed 2021-10-28 | $633.00K 10-Q · filed 2021-10-28 | |
| 2020-06-30 | $2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$749.00K 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | -$2.80M 10-Q · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |